Insights from 2023 ASH Annual Meeting


 

ASH 2023 Insights: "Dual Targeting of SLAMF-7 and CD38 - A Ph2 Study of Isatuximab, Elotuzumab, Pomalidomide and Dexamethasone in R/R MM"

396 views
December 21, 2023
0 Comments
Login to view comments. Click here to Login
Myeloma